


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound of Formula (I), or a pharmaceutically acceptable salt thereof;

wherein the compound of Formula (I) is:




















(I)














wherein:










R_m is a hydrogen or a lower alkyl group;

R_n is:









s is an integer of 0 or 1;

X is:

- (1) $-Y-(CR_4R_4')_p-V-B-T-(CR_4R_4')_p-ONO_2$;
- (2) $-Y-(CR_4R_4')_p-T-C(O)-(CR_4R_4')_o-(CH_2)-ONO_2$;
- (3) $-Y-(CR_4R_4')_p-T-(CH_2)_q-V-(CR_4R_4')_q-(CH_2)-ONO_2$;
- (4) $-Y-(CR_4R_4')_p-V-(CH_2)_q-V-(CR_4R_4')_q-(CH_2)-ONO_2$;
- (5) $-Y-(CR_4R_4')_o-(W)_q-(CR_4R_4')_o-(CH_2)-ONO_2$;
- (6) $-Y-(CR_4R_4')_p-V-(CH_2)_o-(W)_q-(CR_4R_4')_q-(CH_2)-ONO_2$;
- (7) $-Y-(CR_4R_4')_p-(W)_q-(T)_o-(CR_4R_4')_o-(CH_2)-ONO_2$;
- (8) $-Y-(CR_4R_4')_q-C(Z)-V-(CR_4R_4')_q-(CH_2)-ONO_2$;
- (9) $-Y-(CR_4R_4')_p-V-(CR_4R_4')_p-(CH_2)-ONO_2$; or
- (10) $-Y-(CR_4R_4')_p-V-(CH_2)_q-(T)_o-(CR_4R_4')_q-(CH_2)-ONO_2$;

R_4 and R_4' at each occurrence are independently a hydrogen, lower alkyl group, -OH, -CH₂OH, -ONO₂, -NO₂ or -CH₂ONO₂; or R_4 and R_4' taken together with the carbon atom to which they are attached are a cycloalkyl group or a heterocyclic ring;

V is -C(O)-T-, -T-C(O)-, -T-C(O)-T or T-C(O)-C(O)-T;

W is a covalent bond or a carbonyl group;

T at each occurrence is independently an oxygen, (S(O)_o)_o or NR_j;

R_j is a hydrogen, an alkyl group, an aryl group, a heterocyclic ring, an alkylcarbonyl group, an alkylaryl group, an alkylsulfinyl group, an alkylsulfonyl group, an arylsulfinyl group, an arylsulfonyl group, a sulfonamido group, a N-alkylsulfonamido group, a N,N-diarylsulfonamido group, a N-arylsulfonamido group, a N-alkyl-N-arylsulfonamido group, a carboxamido group or a hydroxyl group;

p at each occurrence is independently an integer from 1 to 6;

q at each occurrence is independently an integer from 1 to 3;

o at each occurrence is independently an integer from 0 to 2;

Y is oxygen or sulfur (-S-);

B is either phenyl or (CH₂)_o;

Q' is a cycloalkyl group, a heterocyclic ring or an aryl group;

Z is (=O), (=N-OR₅), (=N-NR₅R'₅) or (=CR₅R'₅);

M and M' are each independently -O⁻ H₃N⁺-(CR₄R'₄)_q-CH₂ONO₂ or -T-(CR₄R'₄)_o-CH₂ONO₂;

R_5 and R_5' at each occurrence are independently a hydrogen, a hydroxyl group, an alkyl group, an aryl group, an alkylsulfonyl group, an arylsulfonyl group, a carboxylic ester, an alkylcarbonyl group, an arylcarbonyl group, a carboxamido group, an alkoxyalkyl group, an alkoxyaryl group, a cycloalkyl group or a heterocyclic ring; and

with the proviso that for X in the compounds of Formulas (I):

when Y is oxygen or sulfur in Formula 5, and W is a covalent bond, at least one R_4 or R_4' must be $-OH$, $-ONO_2$, $-NO_2$ or $-CH_2ONO_2$ or R_4 and R_4' taken together with the carbon atom to which they are attached are a cycloalkyl group or a heterocyclic ring;


when Y is oxygen or sulfur in Formula 7, T is $-N(CH_3)$, W is a covalent bond and R_4 and R_4' are hydrogen, p cannot be the integer 2, and o cannot be the integer 1 in $-(CR_4R_4')_o$;

when Y is oxygen or sulfur in Formula 7, W is a covalent bond, T is oxygen and o is the integer 1, at least one R_4 or R_4' must be $-OH$, $-NO_2$ or $-CH_2ONO_2$ or R_4 and R_4' taken together with the carbon atom to which they are attached are a cycloalkyl group or a heterocyclic ring.


2. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

3. (Previously Presented) The compound of claim 1, wherein X is:


(1)




(2)




(3)




(4)




(5)




(6)




(7)




(8)




(9)




(10)




(11)




(12)




(13)




(14)




(15)




(16)




(17)




(18)



(19)



(20)



wherein:

Y' is oxygen or sulfur;

T' is oxygen, sulfur or NR₆;

X₅ is oxygen, (S(O)_o)_o or NR₆;

R₆ is a hydrogen, a lower alkyl group, an aryl group;

n' and m' are each independently an integer from 0 to 10; and

o is as defined herein.

4. (Currently Amended) The compound of claim 1, wherein the compound of Formula (I) is ~~a nitrosated acemetacin, a nitrosated aceclofenac, a nitrosated alminoprofen, a nitrosated amfenac, a nitrosated bendazac, a nitrosated benoxaprofen, a nitrosated bromfenac, a nitrosated bucloxic acid, a nitrosated butibufen, a nitrosated carprofen, a nitrosated cinmetacin, a nitrosated clopirac, a nitrosated diclofenac, a nitrosated etodolac, a nitrosated felbinac, a nitrosated fenelozic acid, a nitrosated fenbufen, a nitrosated fenoprofen, a nitrosated fentiazac, a nitrosated flunexaprofen, a nitrosated flurbiprofen, a nitrosated ibufenac, a nitrosated ibuprofen, a nitrosated indomethacin, a nitrosated isofezolac, a nitrosated isoxepac, a nitrosated indoprofen, a nitrosated ketoprofen, a nitrosated lonazolac, a nitrosated loxoprofen, a nitrosated metiazinic acid, a nitrosated mofezolac, a nitrosated miroprofen, a nitrosated naproxen, a nitrosated oxaprozin, a nitrosated pirozolac, a nitrosated pirprofen, a nitrosated pranoprofen, a nitrosated protizinic acid, a nitrosated salicylamide, a nitrosated sulindac, a nitrosated suprofen, a nitrosated suxibuzone, a nitrosated tiaprofenic acid, a nitrosated tolmetin, a nitrosated xenbucin, a nitrosated ximoprofen, a nitrosated zaltoprofen a nitrosated zomepirac;~~ the compound of Formula II is ~~a nitrosated aspirin, a nitrosated acemetein, a nitrosated bumadizon, a nitrosated carprofenac, a nitrosated clidanae, a nitrosated diflunisal, a nitrosated enfenamic acid, a nitrosated fendosal, a nitrosated flufenamic acid, a nitrosated flunixin, a nitrosated gentisic acid, a nitrosated ketorolac, a nitrosated meclofenamic acid, a nitrosated mefenamic acid, a nitrosated mesalamine, a nitrosated niflumic acid, a nitrosated salsalate, a nitrosated tolfenamic acid or a nitrosated tropensin~~ substituted with at least one -NO₂ group.

5 – 54 (Cancelled).

55. (Previously Presented) A compound selected from the group consisting of (N-methyl-N-(2-(nitrooxy)ethyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate; (N-ethyl-N-(2-(nitrooxy)ethyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate; (N-methyl-N-(((2-(nitrooxy)ethyl)oxycarbonyl)methyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;

(N-methyl-N-(((3-(nitrooxy)propyl)oxycarbonyl)methyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;
(N-methyl-N-((N-(2-(nitrooxy)ethyl)carbamoyl)methyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;
((2-(nitrooxy)ethyl)oxycarbonyl)methyl 2-(6-methoxy-2-naphthyl)propanoate;
(N-(3-(nitrooxy)propyl)carbamoyl)methyl 2-(6-methoxy-2-naphthyl)propanoate;
((2-((2-(nitrooxy)ethyl)sulfonyl)ethyl)oxycarbonyl)methyl 2-(6-methoxy-2-naphthyl)propanoate;
(2S)-2-(6-methoxy(2-naphthyl))-N-((N-(2-(nitrooxy)ethyl)carbamoyl) methoxy)propanamide;
(N-methyl-N-(3-(nitrooxy)propyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;
2-((2S)-2-(6-methoxy(2-naphthyl))propanoyloxy)ethyl 3-(nitrooxy)-propyl ethane-1,2-dioate;
N-((2S)-2-(6-methoxy(2-naphthyl))propanoylamino)-4 (nitrooxy)butanamide;
or a pharmaceutically acceptable salt thereof.

56. (Withdrawn) A composition comprising at least one compound of claim 55 and a pharmaceutically acceptable carrier.

57. (Cancelled)

58. (Cancelled)